A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis Clinical Trial

Official title:

A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01700985
• Other study ID #: 122-0551-203
• Status: Completed
• Phase: Phase 2
• Start date: May 2012
• Est. completion date: March 2013

Study information

• Verified date: August 2018
• Source: Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: March 2013
• Est. primary completion date: September 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject has a clinical diagnosis of stable plaque psoriasis

• Subject has an ODS score for the Treatment Area of 3 or 4 at study start

Exclusion Criteria:

• Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

• Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.

• Subject has used any phototherapy, photo-chemotherapy or systemic corticosteroid therapy within 30 days prior to study start

• Subject has used any systemic methotrexate, retinoids, cyclosporine or analogous products within 90 days prior to study start

• Subject has used any systemic biologic therapy for the treatment of psoriasis within 5 half-lives of the biologic prior to study start

• Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to study start

• Subject has used topical body (excluding the scalp) psoriasis therapy including coal tar, anthralin, steroids, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to study start

• Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at study start

• Subject is currently using lithium or Plaquenil (hydroxychloroquine)

• Subject is currently using a beta-blocking medication (e.g., propranolol) or ACE (e.g., lisinopril) inhibitor at a dose that has not been stabilized

• Subject is pregnant, lactating, or is planning to become pregnant during the study

• Subject is currently enrolled in an investigational drug or device study

• Subject has used an investigational drug or investigational device treatment within 30 days prior to study start

• Subject has been previously enrolled in this study and treated with a test article

Related Conditions & MeSH terms

• Plaque Psoriasis
• Psoriasis

Intervention

Drug:
• 122-0551
Applied twice daily for two weeks
• Vehicle
Applied twice daily for two weeks

Locations

Country	Name	City	State
United States	DermResearch, Inc.	Austin	Texas
United States	Therapeutics Clinical Research	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Overall Disease Severity (ODS) Score	The percentage of subjects with ODS "treatment success" at EOS where EOS is the subject's last completed visit. "Treatment success" is defined as an ODS of 0 or 1. ODS is measured on a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe/very severe.	baseline and Day 15 (End of Study - EOS)
Secondary	ODS "Treatment Success" at Day 8 and Day 15	The percentage of subjects with ODS "treatment success" at Day 8 and Day 15. "Treatment success" is defined as an ODS of 0 or 1. ODS is measured on a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe/very severe.	baseline, Day 8, and Day 15
Secondary	ODS "Improved" at Day 8 and Day 15	The percentage of subjects rated "improved" with respect to ODS at Days 8 and 15. "Improved" is defined as at least a 2 grade decrease in ODS score relative to baseline. ODS is measured on a 5-point scale: 0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe/very severe.	baseline, Day 8, and Day 15
Secondary	"Treatment Success" for Clinical Signs and Symptoms of Psoriasis	The percentage of subjects rated "treatment success" for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation) at Days 8 and 15. "Treatment success" is defined as a score of 0 or 1 based on a 5-point ordinal scale where 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe.	baseline, Day 8 and Day 15
Secondary	"Improved" for Clinical Signs and Symptoms of Psoriasis	The percentage of subjects rated "improved" for each of the clinical signs and symptoms of psoriasis (scaling, erythema, plaque elevation, pruritus) at Days 8 and 15. "Improved" is defined as at least a 2 grade decrease in score based on a 5-point ordinal scale where 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe.	baseline, Day 8 and Day 15
Secondary	Change in % Body Surface Area (BSA) With Psoriasis	Changes in % BSA with active psoriasis in the Treatment Area at Days 8 and 15.	baseline, Day 8 and Day 15